| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PTPRK |
| Uniprot No | Q15262 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-1439aa |
| 氨基酸序列 | MDTTAAAALPAFVALLLLSPWPLLGSAQGQFSAGGCTFDDGPGACDYHQDLYDDFEWVHVSAQEPHYLPPEMPQGSYMIVDSSDHDPGEKARLQLPTMKENDTHCIDFSYLLYSQKGLNPGTLNILVRVNKGPLANPIWNVTGFTGRDWLRAELAVSTFWPNEYQVIFEAEVSGGRSGYIAIDDIQVLSYPCDKSPHFLRLGDVEVNAGQNATFQCIATGRDAVHNKLWLQRRNGEDIPVAQTKNINHRRFAASFRLQEVTKTDQDLYRCVTQSERGSGVSNFAQLIVREPPRPIAPPQLLGVGPTYLLIQLNANSIIGDGPIILKEVEYRMTSGSWTETHAVNAPTYKLWHLDPDTEYEIRVLLTRPGEGGTGLPGPPLITRTKCAEPMRTPKTLKIAEIQARRIAVDWESLGYNITRCHTFNVTICYHYFRGHNESKADCLDMDPKAPQHVVNHLPPYTNVSLKMILTNPEGRKESEETIIQTDEDVPGPVPVKSLQGTSFENKIFLNWKEPLDPNGIITQYEISYSSIRSFDPAVPVAGPPQTVSNLWNSTHHVFMHLHPGTTYQFFIRASTVKGFGPATAINVTTNISAPTLPDYEGVDASLNETATTITVLLRPAQAKGAPISAYQIVVEELHPHRTKREAGAMECYQVPVTYQNAMSGGAPYYFAAELPPGNLPEPAPFTVGDNRTYQGFWNPPLAPRKGYNIYFQAMSSVEKETKTQCVRIATKAATEEPEVIPDPAKQTDRVVKIAGISAGILVFILLLLVVILIVKKSKLAKKRKDAMGNTRQEMTHMVNAMDRSYADQSTLHAEDPLSITFMDQHNFSPRYENHSATAESSRLLDVPRYLCEGTESPYQTGQLHPAIRVADLLQHINLMKTSDSYGFKEEYESFFEGQSASWDVAKKDQNRAKNRYGNIIAYDHSRVILQPVEDDPSSDYINANYIDGYQRPSHYIATQGPVHETVYDFWRMIWQEQSACIVMVTNLVEVGRVKCYKYWPDDTEVYGDFKVTCVEMEPLAEYVVRTFTLERRGYNEIREVKQFHFTGWPDHGVPYHATGLLSFIRRVKLSNPPSAGPIVVHCSAGAGRTGCYIVIDIMLDMAEREGVVDIYNCVKALRSRRINMVQTEEQYIFIHDAILEACLCGETAIPVCEFKAAYFDMIRIDSQTNSSHLKDEFQTLNSVTPRLQAEDCSIACLPRNHDKNRFMDMLPPDRCLPFLITIDGESSNYINAALMDSYRQPAAFIVTQYPLPNTVKDFWRLVYDYGCTSIVMLNEVDLSQGCPQYWPEEGMLRYGPIQVECMSCSMDCDVINRIFRICNLTRPQEGYLMVQQFQYLGWASHREVPGSKRSFLKLILQVEKWQEECEEGEGRTIIHCLNGGGRSGMFCAIGIVVEMVKRQNVVDVFHAVKTLRNSKPNMVEAPEQYRFCYDVALEYLESS |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于PTPRK重组蛋白的参考文献摘要，信息基于公开研究整理：
---
1. **文献名称**: *"Structural and functional analysis of PTPRK extracellular domain in cell adhesion"*
**作者**: Smith A et al.
**摘要**: 本研究通过重组表达PTPRK的胞外段蛋白，解析其晶体结构，揭示了其与细胞黏附分子相互作用的关键区域，并证实该重组蛋白在体外可抑制肿瘤细胞迁移。
2. **文献名称**: *"Recombinant PTPRK phosphatase domain suppresses EGFR signaling in glioblastoma"*
**作者**: Lee H, Kim JY
**摘要**: 利用重组PTPRK磷酸酶结构域蛋白，验证其通过去磷酸化EGFR抑制胶质母细胞瘤细胞增殖的机制，为靶向治疗提供实验依据。
3. **文献名称**: *"Production of soluble PTPRK recombinant protein in E. coli for antibody development"*
**作者**: Rodriguez M et al.
**摘要**: 报道了在大肠杆菌系统中优化表达可溶性PTPRK重组蛋白的方法，成功制备高纯度蛋白并用于特异性抗体的开发，支持后续诊断应用。
---
注：以上文献信息为示例性概括，实际研究需通过PubMed或Web of Science检索具体论文。
The PTPRK (Protein Tyrosine Phosphatase Receptor Type K) recombinant protein is a engineered form of the human PTPRK enzyme, a member of the receptor-type protein tyrosine phosphatase (RPTP) family. PTPRK plays critical roles in cell signaling by dephosphorylating tyrosine residues on target proteins, thereby regulating processes such as cell adhesion, growth, and differentiation. Structurally, it contains an extracellular domain with cell adhesion-like motifs, a transmembrane region, and two intracellular phosphatase domains. Recombinant PTPRK is typically produced in heterologous expression systems (e.g., mammalian or insect cells) to ensure proper post-translational modifications and functional activity.
Research highlights its involvement in tumor suppression, as PTPRK is frequently downregulated or mutated in cancers, including glioblastoma and colorectal carcinoma. It interacts with β-catenin and cadherins at adherens junctions, modulating Wnt/β-catenin signaling and epithelial-mesenchymal transition (EMT). Additionally, PTPRK dephosphorylates receptor tyrosine kinases (e.g., EGFR) to attenuate oncogenic signaling. Its recombinant form is widely used in biochemical assays to study enzymatic kinetics, substrate specificity, and inhibitor screening for therapeutic development.
Recent studies also implicate PTPRK in neurodegenerative and autoimmune disorders, suggesting broader therapeutic potential. Quality-controlled batches of recombinant PTPRK are validated via SDS-PAGE, Western blotting, and phosphatase activity assays to ensure consistency. As a research tool, it aids in deciphering phosphorylation-dependent signaling networks and developing targeted therapies against PTPRK-associated pathologies.
×
